AUPH Q2 2025 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M+22.4% YoY

Gross Profit

$63M89.8% margin

Operating Income

$20M28.7% margin

Net Income

$22M30.7% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+12.1%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$44M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$503M

Total Liabilities

$167M

Stockholders' Equity

$335M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$57M	+22.4%
Gross Profit	$63M	$48M	+30.3%
Operating Income	$20M	-$2M	+1427.4%
Net Income	$22M	$722,000	+2879.6%

Revenue Segments

Product

$67M95%

License, Collaboration and Royalty Revenue

$3M5%